摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2R,3 S,5R)-2-(2,5-difluorophenyl)-5-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)tetrahydro-2H-pyran-3-amine | 1601479-76-8

中文名称
——
中文别名
——
英文名称
(2R,3 S,5R)-2-(2,5-difluorophenyl)-5-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)tetrahydro-2H-pyran-3-amine
英文别名
(2R,3S,5R)-5-(1,3,3a,4,6,6a-hexahydrofuro[3,4-c]pyrrol-5-yl)-2-(2,5-difluorophenyl)oxan-3-amine
(2R,3 S,5R)-2-(2,5-difluorophenyl)-5-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)tetrahydro-2H-pyran-3-amine化学式
CAS
1601479-76-8
化学式
C17H22F2N2O2
mdl
——
分子量
324.371
InChiKey
RNIQPKSPFHAEGK-IWZOOHDWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    23
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.65
  • 拓扑面积:
    47.7
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 2-PHENYL-5-HETEROCYCLYL-TETRAHYDRO-2H-PYRAN-3-AMINE COMPOUNDS FOR USE IN THE TREATMENT OF DIABETES AND ITS ASSOCIATED DISORDERS
    申请人:CADILA HEALTHCARE LIMITED
    公开号:US20150246025A1
    公开(公告)日:2015-09-03
    The present invention relates to novel compounds of the general formula (I) their tautomeric forms, their enantiomers, their diastereoisomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment or prevention of diabetes mellitus (DM), obesity and other metabolic disorders. The invention also relates to process for the manufacture of said compounds, and pharmaceutical compositions containing them and their use.
    本发明涉及一种新颖的化合物,其通式为(I),其互变异构体形式,其对映异构体,其顺反异构体,其药学上可接受的盐或前药,用于治疗或预防糖尿病(DM),肥胖症和其他代谢性疾病。本发明还涉及制备所述化合物的方法,以及包含它们的药物组合物和它们的用途。
  • EP2909199A1
    申请人:——
    公开号:EP2909199A1
    公开(公告)日:2015-08-26
  • [EN] 2-PHENYL-5-HETEROCYCLYL-TETRAHYDRO-2H-PYRAN-3-AMINE COMPOUNDS FOR USE IN THE TREATMENT OF DIABETES AND ITS ASSOCIATED DISORDERS<br/>[FR] COMPOSÉS DE 2-PHÉNYL-5-HÉTÉROCYCLYL-TÉTRAHYDRO-2H-PYRAN-3-AMINE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU DIABÈTE ET DE SES TROUBLES ASSOCIÉS
    申请人:CADILA HEALTHCARE LTD
    公开号:WO2014061031A1
    公开(公告)日:2014-04-24
    The present invention relates to novel compounds of the general formula (I) their tautomeric forms, their enantiomers, their diastereoisomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment or prevention of diabetes mellitus (DM), obesity and other metabolic disorders. The invention also relates to process for the manufacture of said compounds, and pharmaceutical compositions containing them and their use.
    本发明涉及一般式(I)的新化合物,其互变异构体形式、其对映体、其二对映异构体、其药学上可接受的盐或其前药,用于治疗或预防糖尿病(DM)、肥胖和其他代谢紊乱。该发明还涉及制备所述化合物的方法,以及含有它们的药物组合物及其用途。
查看更多

同类化合物

顺式-六氢呋喃并[3,4-C]吡咯 甲基4-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸酯 氮杂环丁烷并[1,2-a]呋喃并[2,3-c]吡咯 夫沙瑞汀A 呋喃并吡咯甲酸 六氢-1H-呋喃并[3,4-c]吡咯 六氢-1H-呋喃并[3,4-C]吡咯 八氢-呋喃并[3,2-c]吡啶 乙基4,6-二氢-5H-呋喃并[2,3-c]吡咯-5-羧酸酯 6H-呋喃并[2,3-b]吡咯-5-羧酸甲酯 6-甲基-6H-呋喃并[2,3-b]吡咯-5-羧酸 6-甲基-6H-呋喃并[2,3-b]吡咯-5-甲酰肼 4H-呋喃并[3,2-b]吡咯-5-羧酸乙酯 4H-呋喃并[3,2-b]吡咯-5-羧酸,2-甲酰基-,甲基酯 4H-呋喃并[3,2-b]吡咯 4H-呋喃并[3,2-B!吡咯-5-羧酸甲酯 4-甲基呋喃[3,2-b]吡咯-5-羧酸乙酯 4-甲基-4H-呋喃并[3,2-b]吡咯 4-甲基-4H-呋喃并[3,2-B]吡咯-5-甲酸 365-苄基六氢-1H-呋喃[34-c]吡咯 3-溴-4H-呋喃并[3,2-b]吡咯-5-羧酸 3-溴-4H-呋喃并[3,2-b]吡咯-5-甲酸乙酯 2-苯基-4H-呋喃并[3,2-b]吡咯-5-羧酸 2-甲酰基-6-甲基-6H-呋喃并[2,3-b]吡咯-5-羧酸 2-甲酰基-4-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸甲酯 2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸甲酯 2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸乙酯 2-甲基-4H-呋喃并[3,2-b]吡咯-5-羧酸 2-溴-4H-呋喃并[3,2-b]吡咯-5-羧酸乙酯 2-溴-4H-呋喃并[3,2-B]吡咯-5-羧酸 2-(4-甲氧基苯基)-4H-呋喃并[3,2-b]吡咯-5-羧酸乙酯 2-(4-甲氧基苯基)-4H-呋喃并[3,2-b]吡咯-5-羧酸 2,3,3A,4-四氢-5H-呋喃并[3,2-b]吡咯-5-酮 1-(4H-呋喃并[3,2-b]吡咯-4-基)乙酮 1-(2-甲基-4H-呋喃并[3,2-b]吡咯-4-基)乙酮 (9ci)-1-甲基-1H-呋喃并[3,4-b]吡咯-4,6-二酮 (4-甲基-4H-呋喃并[3,2-b]吡咯-5-基)甲醇 (3aR,6aR)-4-乙酰基六氢-2H-呋喃并[3,2-b]吡咯-2-酮 5-(3-chloropropyl)hexahydro-1H-furo[3,4-c]pyrrole Methyl 2-[2-cyano-2-(methoxycarbonyl)vinyl]-6-methoxyfuro[2,3-b]pyrrole-5-carboxylate Methyl 6-methoxymethyl-2-(3,3,6,6-tetramethyl-1(2H),8(7H)-dioxo-3,4,5,6-tetrahydro-9H-xanthen-9-yl)furo[2,3-b]pyrrole-5-carboxylate methyl 2-cyano-6-(methoxymethyl)furo[2,3-b]pyrrole-5-carboxylate Methyl 2-(2,2-dicyanovinyl)-6-methoxymethylfuro[2,3-b]pyrrole-5-carboxylate (1R,5S,1'S)-1,5-dimethyl-8-phenylethyl-2-oxa-8-azabicyclo[3.3.0]octane-3,7-dione (1S,5R,1'S)-1,5-dimethyl-8-phenylethyl-2-oxa-8-azabicyclo[3.3.0]octane-3,7-dione {3-[2-(4-chloro-phenyl)-6-oxo-4-thioxo-6H-1-oxa-3b,5-diaza-cyclopenta[a]pentalen-5-yl]-propyl}-phosphonic acid diethyl ester methyl 4-(3,4-dichlorobenzyl)-2-formylfuro[3,2-b]pyrrole-carboxylate (3aR,6aS)-5-benzyl-3a,6a-dimethyltetrahydro-1H-furo[3,4-c]pyrrole-1,3(3aH)-dione (1R,2R,6R,8R,15S)-10,14-aza-4,4-dimethyl-11-oxo-1-mesyloxy-3,5,7-trioxa-tetracyclo[7.6.0.02,6.010,15]pentadecane 5-methyl-1,3-bis(3-oxobutyl)dihydro-1H-furo[3,4-c]pyrrole-4,6(5H,6aH)-dione